메뉴 건너뛰기




Volumn 87, Issue 2, 2012, Pages 161-171

My treatment approach to patients with diffuse large B-cell lymphoma

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CISPLATIN; CRIZOTINIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE; VINDESINE;

EID: 84856679171     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2011.11.007     Document Type: Article
Times cited : (54)

References (92)
  • 1
    • 0015305553 scopus 로고
    • Combination sequential chemotherapy in advanced reticulum cell sarcoma
    • Levitt M, Marsh JC, DeConti RC, et al. Combination sequential chemotherapy in advanced reticulum cell sarcoma. Cancer. 1972;29(3):630-636.
    • (1972) Cancer , vol.29 , Issue.3 , pp. 630-636
    • Levitt, M.1    Marsh, J.C.2    DeConti, R.C.3
  • 3
    • 34347378243 scopus 로고    scopus 로고
    • How I treat patients with diffuse large B-cell lymphoma
    • DOI 10.1182/blood-2007-01-041871
    • Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110(1):29-36. (Pubitemid 47026815)
    • (2007) Blood , vol.110 , Issue.1 , pp. 29-36
    • Armitage, J.O.1
  • 4
    • 0027444652 scopus 로고
    • A predictive model for aggressive non-Hodgkin's lymphoma; the International Non-Hodgkin's Lymphoma Prognostic Factors Project
    • [see comments]
    • A predictive model for aggressive non-Hodgkin's lymphoma; the International Non-Hodgkin's Lymphoma Prognostic Factors Project [see comments]. N Engl J Med. 1993;329(14):987-994.
    • (1993) N Engl J Med , vol.329 , Issue.14 , pp. 987-994
  • 6
    • 77952477025 scopus 로고    scopus 로고
    • Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era
    • Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-2380.
    • (2010) J Clin Oncol , vol.28 , Issue.14 , pp. 2373-2380
    • Ziepert, M.1    Hasenclever, D.2    Kuhnt, E.3
  • 8
    • 80054750428 scopus 로고    scopus 로고
    • R-CHOP14 versus R-CHOP21: Results of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma
    • [Abstract #8000]
    • Cunningham D. R-CHOP14 versus R-CHOP21: results of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol. 2011;29(15S):504s. [Abstract #8000].
    • (2011) J Clin Oncol , vol.29 , Issue.15 S
    • Cunningham, D.1
  • 9
    • 82755184062 scopus 로고    scopus 로고
    • R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the second interim analysis of the LNH03-6B GELA Study
    • [Abstract 106]
    • Delarue R, Tilly H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the second interim analysis of the LNH03-6B GELA Study. Ann Oncol. 2011;22(suppl 4). [Abstract 106].
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 4
    • Delarue, R.1    Tilly, H.2    Salles, G.3
  • 10
    • 82255186682 scopus 로고    scopus 로고
    • Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial
    • Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. The Lancet. 2011;378:1858-1867.
    • (2011) The Lancet , vol.378 , pp. 1858-1867
    • Recher, C.1    Coiffier, B.2    Haioun, C.3
  • 14
    • 79959954107 scopus 로고    scopus 로고
    • Diffuse large B-cell lymphoma with involvement of the kidney: Outcome and risk of central nervous system relapse
    • Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica. 2011;96(7):1002-1007.
    • (2011) Haematologica , vol.96 , Issue.7 , pp. 1002-1007
    • Villa, D.1    Connors, J.M.2    Sehn, L.H.3    Gascoyne, R.D.4    Savage, K.J.5
  • 15
    • 0033660953 scopus 로고    scopus 로고
    • High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma
    • Alvarnas JC, Negrin RS, Horning SJ, et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2000;6(3A):352-358.
    • (2000) Biol Blood Marrow Transplant , vol.6 , Issue.3 A , pp. 352-358
    • Alvarnas, J.C.1    Negrin, R.S.2    Horning, S.J.3
  • 16
    • 85171907933 scopus 로고    scopus 로고
    • Systemic and intrathecal chemotherapy followed by high-dose chemotherapy with autologous stem cell aggressive lymphomas; a potentially curative approach?
    • [Abstract 258]
    • Korfel A, Fischer L, Mohle R, et al. Systemic and intrathecal chemotherapy followed by high-dose chemotherapy with autologous stem cell aggressive lymphomas; a potentially curative approach? Ann Oncol. 2011;22(suppl 4). [Abstract 258].
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 4
    • Korfel, A.1    Fischer, L.2    Mohle, R.3
  • 17
    • 0033736141 scopus 로고    scopus 로고
    • Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients
    • Groupe d'Etudes des Lymphomes de l'Adulte
    • Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol. 2000;11(6):685-690.
    • (2000) Ann Oncol , vol.11 , Issue.6 , pp. 685-690
    • Haioun, C.1    Besson, C.2    Lepage, E.3
  • 19
    • 33846531961 scopus 로고    scopus 로고
    • Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - A survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    • DOI 10.1093/annonc/mdl327
    • Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18(1):149-157. (Pubitemid 46152515)
    • (2007) Annals of Oncology , vol.18 , Issue.1 , pp. 149-157
    • Boehme, V.1    Zeynalova, S.2    Kloess, M.3    Loeffler, M.4    Kaiser, U.5    Pfreundschuh, M.6    Schmitz, N.7
  • 20
    • 58149354864 scopus 로고    scopus 로고
    • Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: A 20-year follow-up analysis of SWOG 8516 - The Southwest Oncology Group
    • Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 - the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114-119.
    • (2009) J Clin Oncol , vol.27 , Issue.1 , pp. 114-119
    • Bernstein, S.H.1    Unger, J.M.2    Leblanc, M.3    Friedberg, J.4    Miller, T.P.5    Fisher, R.I.6
  • 21
    • 77953351708 scopus 로고    scopus 로고
    • Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy
    • Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21(5):1046-1052.
    • (2010) Ann Oncol , vol.21 , Issue.5 , pp. 1046-1052
    • Villa, D.1    Connors, J.M.2    Shenkier, T.N.3    Gascoyne, R.D.4    Sehn, L.H.5    Savage, K.J.6
  • 22
    • 23244455813 scopus 로고    scopus 로고
    • Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma
    • DOI 10.1016/j.hoc.2005.05.003, PII S0889858805000407, Central Nervous System Lymphomas
    • Bierman P, Giglio P. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 2005;19(4):597-609. (Pubitemid 41096708)
    • (2005) Hematology/Oncology Clinics of North America , vol.19 , Issue.4 , pp. 597-609
    • Bierman, P.1    Giglio, P.2
  • 23
    • 0025338486 scopus 로고
    • Bone marrow involvement by non-Hodgkin's lymphoma: The clinical significance of morphologic discordance between the lymph node and bone marrow
    • Conlan MG, Bast M, Armitage JO, Weisenburger DD; Nebraska Lymphoma Study Group. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. J Clin Oncol. 1990;8(7):1163-1172. (Pubitemid 20195626)
    • (1990) Journal of Clinical Oncology , vol.8 , Issue.7 , pp. 1163-1172
    • Conlan, M.G.1    Bast, M.2    Armitage, J.O.3    Weisenburger, D.D.4
  • 24
    • 79955015019 scopus 로고    scopus 로고
    • Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP
    • Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29(11):1452-1457.
    • (2011) J Clin Oncol , vol.29 , Issue.11 , pp. 1452-1457
    • Sehn, L.H.1    Scott, D.W.2    Chhanabhai, M.3
  • 25
    • 19944428085 scopus 로고    scopus 로고
    • High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: The role of flow cytometry versus cytology
    • DOI 10.1182/blood-2004-05-1982
    • Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105(2):496-502. (Pubitemid 40070727)
    • (2005) Blood , vol.105 , Issue.2 , pp. 496-502
    • Hegde, U.1    Filie, A.2    Little, R.F.3    Janik, J.E.4    Grant, N.5    Steinberg, S.M.6    Dunleavy, K.7    Jaffe, E.S.8    Abati, A.9    Stetler-Stevenson, M.10    Wilson, W.H.11
  • 26
    • 63049126670 scopus 로고    scopus 로고
    • Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: Improved sensitivity of flow cytometry
    • Quijano S, López A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009;27(9):1462-1469.
    • (2009) J Clin Oncol , vol.27 , Issue.9 , pp. 1462-1469
    • Quijano, S.1    López, A.2    Manuel Sancho, J.3
  • 27
    • 77957940539 scopus 로고    scopus 로고
    • Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy
    • Phan J, Mazloom A, Jeffrey Medeiros L, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28(27):4170-4176.
    • (2010) J Clin Oncol , vol.28 , Issue.27 , pp. 4170-4176
    • Phan, J.1    Mazloom, A.2    Jeffrey Medeiros, L.3
  • 28
    • 33646004738 scopus 로고    scopus 로고
    • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the Mab-Thera International Trial (MInT) Group
    • Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mab-Thera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
    • (2006) Lancet Oncol , vol.7 , Issue.5 , pp. 379-391
    • Pfreundschuh, M.1    Trümper, L.2    Osterborg, A.3
  • 29
    • 85171910448 scopus 로고    scopus 로고
    • 6-Year follow-up of the MINT study suggests a role for radiotherapy to bulky disease
    • [Abstract 029]
    • Pfreundschuh M, Kuhnt E, Truemper L, et al. 6-Year follow-up of the MINT study suggests a role for radiotherapy to bulky disease. Ann Oncol. 2011;22(suppl 4). [Abstract 029].
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 4
    • Pfreundschuh, M.1    Kuhnt, E.2    Truemper, L.3
  • 30
    • 79251540892 scopus 로고    scopus 로고
    • The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans
    • Dorth JA, Chino JP, Prosnitz LR, et al. The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. Ann Oncol. 2011;22(2):405-410.
    • (2011) Ann Oncol , vol.22 , Issue.2 , pp. 405-410
    • Dorth, J.A.1    Chino, J.P.2    Prosnitz, L.R.3
  • 31
    • 57349104217 scopus 로고    scopus 로고
    • R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome: A GEL/TAMO study
    • Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome: A GEL/TAMO study. Haematologica. 2008;93(12):1829-1836.
    • (2008) Haematologica , vol.93 , Issue.12 , pp. 1829-1836
    • Martin, A.1    Conde, E.2    Arnan, M.3
  • 32
    • 85171910368 scopus 로고    scopus 로고
    • Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP and who respond to salvage chemotherapy
    • [Abstract 076]
    • Moore S, Peggs K, Thomson KJ, et al. Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP and who respond to salvage chemotherapy. Ann Oncol. 2011;22(suppl 4). [Abstract 076].
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 4
    • Moore, S.1    Peggs, K.2    Thomson, K.J.3
  • 33
    • 80755143466 scopus 로고    scopus 로고
    • The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A Bio-CORAL study
    • Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a Bio-CORAL study. J Clin Oncol. 2011;29(31):4079-4087.
    • (2011) J Clin Oncol , vol.29 , Issue.31 , pp. 4079-4087
    • Thieblemont, C.1    Briere, J.2    Mounier, N.3
  • 34
    • 80052980811 scopus 로고    scopus 로고
    • Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP +/- R for eight cycles of CHOP +/- R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgin lymphoma (NHL)
    • Stiff PJ. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP +/- R for eight cycles of CHOP +/- R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgin lymphoma (NHL). J Clin Oncol. 2011;29(15S):504s.
    • (2011) J Clin Oncol , vol.29 , Issue.15
    • Stiff, P.J.1
  • 35
    • 72649090031 scopus 로고    scopus 로고
    • A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: A report from the CIBMTR
    • Lazarus HM, Zhang MJ, Carreras J, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010;16(1):35-45.
    • (2010) Biol Blood Marrow Transplant , vol.16 , Issue.1 , pp. 35-45
    • Lazarus, H.M.1    Zhang, M.J.2    Carreras, J.3
  • 36
    • 79954441806 scopus 로고    scopus 로고
    • Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: An analysis of the European Group for Blood and Marrow Transplantation Registry
    • van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. 2011;29(10):1342-1348.
    • (2011) J Clin Oncol , vol.29 , Issue.10 , pp. 1342-1348
    • Van Kampen, R.J.1    Canals, C.2    Schouten, H.C.3
  • 37
    • 72649091641 scopus 로고    scopus 로고
    • Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: Report of the Société Franòaise de Greffe de Moelle et de thérapie Cellulaire
    • Sirvent A, Dhedin N, Michallet M, et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the SociétéFranòaise de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant. 2010;16(1):78-85.
    • (2010) Biol Blood Marrow Transplant , vol.16 , Issue.1 , pp. 78-85
    • Sirvent, A.1    Dhedin, N.2    Michallet, M.3
  • 38
    • 77957066815 scopus 로고    scopus 로고
    • Surveillance computed tomography scans for patients with lymphoma: Is the risk worth the benefits?
    • Shenoy P, Sinha R, Tumeh JW, Lechowicz MJ, Flowers CR. Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits? Clin Lymphoma Myeloma Leuk. 2010;10(4):270-277.
    • (2010) Clin Lymphoma Myeloma Leuk , vol.10 , Issue.4 , pp. 270-277
    • Shenoy, P.1    Sinha, R.2    Tumeh, J.W.3    Lechowicz, M.J.4    Flowers, C.R.5
  • 39
    • 34547112263 scopus 로고    scopus 로고
    • 67gallium scintigraphy in the evaluation of lymphoma: Relation to histologic subtypes based on the World Health Organization classification
    • DOI 10.1002/cncr.22807
    • Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110(3):652-659. (Pubitemid 47106156)
    • (2007) Cancer , vol.110 , Issue.3 , pp. 652-659
    • Tsukamoto, N.1    Kojima, M.2    Hasegawa, M.3    Oriuchi, N.4    Matsushima, T.5    Yokohama, A.6    Saitoh, T.7    Handa, H.8    Endo, K.9    Murakami, H.10
  • 40
    • 36348942458 scopus 로고    scopus 로고
    • The role of FDG-PET scans in patients with lymphoma
    • DOI 10.1182/blood-2007-06-097238
    • Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110(10):3507-3516. (Pubitemid 350159614)
    • (2007) Blood , vol.110 , Issue.10 , pp. 3507-3516
    • Seam, P.1    Juweid, M.E.2    Cheson, B.D.3
  • 42
    • 53049088385 scopus 로고    scopus 로고
    • Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma
    • Elstrom RL, Leonard JP, Coleman M, Brown RK. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol. 2008;19(10):1770-1773.
    • (2008) Ann Oncol , vol.19 , Issue.10 , pp. 1770-1773
    • Elstrom, R.L.1    Leonard, J.P.2    Coleman, M.3    Brown, R.K.4
  • 43
    • 34250698039 scopus 로고    scopus 로고
    • 2-[18F]Fluoro-2-Deoxyglucose Positron-Emission Tomography in Staging, Response Evaluation, and Treatment Planning of Lymphomas
    • DOI 10.1016/j.semradonc.2007.02.005, PII S1053429607000161, Lymphoma
    • Specht L. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin Radiat Oncol. 2007;17(3):190-197. (Pubitemid 46963030)
    • (2007) Seminars in Radiation Oncology , vol.17 , Issue.3 , pp. 190-197
    • Specht, L.1
  • 44
    • 0033566341 scopus 로고    scopus 로고
    • 18F- fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
    • Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94(2):429-433. (Pubitemid 29323856)
    • (1999) Blood , vol.94 , Issue.2 , pp. 429-433
    • Jerusalem, G.1    Beguin, Y.2    Fassotte, M.F.3    Najjar, F.4    Paulus, P.5    Rigo, P.6    Fillet, G.7
  • 46
    • 0033996693 scopus 로고    scopus 로고
    • 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas
    • Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol. 2000;11(suppl 1):147-150.
    • (2000) Ann Oncol , vol.11 , Issue.SUPPL. 1 , pp. 147-150
    • Mikhaeel, N.G.1    Timothy, A.R.2    Hain, S.F.3    O'Doherty, M.J.4
  • 47
    • 0035676671 scopus 로고    scopus 로고
    • Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma
    • DOI 10.1046/j.1365-2141.2001.03147.x
    • Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol. 2001;115(4):793-800. (Pubitemid 34042895)
    • (2001) British Journal of Haematology , vol.115 , Issue.4 , pp. 793-800
    • Naumann, R.1    Vaic, A.2    Beuthien-Baumann, B.3    Bredow, J.4    Kropp, J.5    Kittner, T.6    Franke, W.-G.7    Ehninger, G.8
  • 48
    • 61649101731 scopus 로고    scopus 로고
    • Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: Integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria
    • Dupuis J, Itti E, Rahmouni A, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20(3):503-507.
    • (2009) Ann Oncol , vol.20 , Issue.3 , pp. 503-507
    • Dupuis, J.1    Itti, E.2    Rahmouni, A.3
  • 51
    • 0036739436 scopus 로고    scopus 로고
    • Early restaging positron emission tomography with (18)F- fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
    • Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13(9):1356-1363.
    • (2002) Ann Oncol , vol.13 , Issue.9 , pp. 1356-1363
    • Spaepen, K.1    Stroobants, S.2    Dupont, P.3
  • 52
    • 80054098574 scopus 로고    scopus 로고
    • Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
    • Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118(15):4053-4061.
    • (2011) Blood , vol.118 , Issue.15 , pp. 4053-4061
    • Micallef, I.N.1    Maurer, M.J.2    Wiseman, G.A.3
  • 53
    • 77951638691 scopus 로고    scopus 로고
    • Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma
    • Moskowitz CH, Schöder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010;28(11):1896-1903.
    • (2010) J Clin Oncol , vol.28 , Issue.11 , pp. 1896-1903
    • Moskowitz, C.H.1    Schöder, H.2    Teruya-Feldstein, J.3
  • 54
    • 69549145060 scopus 로고    scopus 로고
    • Limited-stage DLBCL patients with a negative PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone
    • [Abstract 052]
    • Sehn LH, Savage KJ, Hoskins P, et al. Limited-stage DLBCL patients with a negative PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone. Ann Oncol. 2008;19(suppl 4). [Abstract 052].
    • (2008) Ann Oncol , vol.19 , Issue.SUPPL. 4
    • Sehn, L.H.1    Savage, K.J.2    Hoskins, P.3
  • 55
    • 80051600214 scopus 로고    scopus 로고
    • Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy
    • Corazzelli G, Frigeri F, Arcamone M, et al. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy. Br J Haematol. 2011;154(5):579-589.
    • (2011) Br J Haematol , vol.154 , Issue.5 , pp. 579-589
    • Corazzelli, G.1    Frigeri, F.2    Arcamone, M.3
  • 56
    • 79955485192 scopus 로고    scopus 로고
    • Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas
    • Weidmann E, Neumann A, Fauth F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011;22(8):1839-1844.
    • (2011) Ann Oncol , vol.22 , Issue.8 , pp. 1839-1844
    • Weidmann, E.1    Neumann, A.2    Fauth, F.3
  • 57
    • 79955812219 scopus 로고    scopus 로고
    • R-CHOP with etoposide substituted for doxorubicin (R-CEOP): Excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines
    • Moccia AA, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines. Blood. 2009;114(22):170.
    • (2009) Blood , vol.114 , Issue.22 , pp. 170
    • Moccia, A.A.1    Schaff, K.2    Hoskins, P.3
  • 62
    • 0029905515 scopus 로고    scopus 로고
    • Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha2b
    • Wilson WH, Kingma DW, Raffeld M, Wittes RE, Jaffe ES. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood. 1996;87(11):4531-4537. (Pubitemid 26162358)
    • (1996) Blood , vol.87 , Issue.11 , pp. 4531-4537
    • Wilson, W.H.1    Kingma, D.W.2    Raffeld, M.3    Wittes, R.E.4    Jaffe, E.S.5
  • 63
    • 79960685420 scopus 로고    scopus 로고
    • How I treat primary CNS lymphoma
    • Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011;118(3):510-522.
    • (2011) Blood , vol.118 , Issue.3 , pp. 510-522
    • Ferreri, A.J.1
  • 64
    • 79953304056 scopus 로고    scopus 로고
    • Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy
    • Khimani NB, Ng AK, Chen YH, Catalano P, Silver B, Mauch PM. Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy. Ann Oncol. 2011;22(4):979-984.
    • (2011) Ann Oncol , vol.22 , Issue.4 , pp. 979-984
    • Khimani, N.B.1    Ng, A.K.2    Chen, Y.H.3    Catalano, P.4    Silver, B.5    Mauch, P.M.6
  • 65
    • 79960239204 scopus 로고    scopus 로고
    • First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: Final results of an international phase II trial
    • Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29(20):2766-2772.
    • (2011) J Clin Oncol , vol.29 , Issue.20 , pp. 2766-2772
    • Vitolo, U.1    Chiappella, A.2    Ferreri, A.J.3
  • 66
    • 18744370725 scopus 로고    scopus 로고
    • Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group
    • Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20-27.
    • (2003) J Clin Oncol , vol.21 , Issue.1 , pp. 20-27
    • Zucca, E.1    Conconi, A.2    Mughal, T.I.3
  • 67
    • 0029060546 scopus 로고
    • Testicular lymphoma: Late relapses and poor outcome despite doxorubicin-based therapy
    • Touroutoglou N, Dimopoulos MA, Younes A, et al. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. J Clin Oncol. 1995;13(6):1361-1367.
    • (1995) J Clin Oncol , vol.13 , Issue.6 , pp. 1361-1367
    • Touroutoglou, N.1    Dimopoulos, M.A.2    Younes, A.3
  • 71
    • 52649165593 scopus 로고    scopus 로고
    • The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma
    • Ferreri AJ, Dognini GP, Bairey O, et al. The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma. Br J Haematol. 2008;143(2):253-257.
    • (2008) Br J Haematol , vol.143 , Issue.2 , pp. 253-257
    • Ferreri, A.J.1    Dognini, G.P.2    Bairey, O.3
  • 72
    • 69149087791 scopus 로고    scopus 로고
    • Presentation and management of intravascular large B-cell lymphoma
    • Shimada K, Kinoshita T, Naoe T, Nakamura S. Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol. 2009;10(9):895-902.
    • (2009) Lancet Oncol , vol.10 , Issue.9 , pp. 895-902
    • Shimada, K.1    Kinoshita, T.2    Naoe, T.3    Nakamura, S.4
  • 73
    • 85171929485 scopus 로고    scopus 로고
    • Prognostic significance of circulating lymphoma cells in newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    • [Abstract 2947]
    • Muringampurath-John D, Flowers CR, Jabbar AA, et al. Prognostic significance of circulating lymphoma cells in newly diagnosed diffuse large B-cell lymphoma (DLBCL). Blood. 2009;114(22):1151. [Abstract 2947].
    • (2009) Blood , vol.114 , Issue.22 , pp. 1151
    • Muringampurath-John, D.1    Flowers, C.R.2    Jabbar, A.A.3
  • 74
    • 70349691319 scopus 로고    scopus 로고
    • B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma
    • Swerdlow SH, Campo E, Harris NL, et al, eds. 4th ed. Lyon, France: IARC Press
    • Jaffe ES, Stein H, Swerdlow SH, Campo E, Pileri SA, Harris NL. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:267-268.
    • (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , pp. 267-268
    • Jaffe, E.S.1    Stein, H.2    Swerdlow, S.H.3    Campo, E.4    Pileri, S.A.5    Harris, N.L.6
  • 75
    • 80054045437 scopus 로고    scopus 로고
    • BCL2 and MYC dual-hit lymphoma/leukemia
    • Tomita N. BCL2 and MYC dual-hit lymphoma/leukemia. J Clin Exp Hematop. 2011;51(1):7-12.
    • (2011) J Clin Exp Hematop , vol.51 , Issue.1 , pp. 7-12
    • Tomita, N.1
  • 76
    • 79952154009 scopus 로고    scopus 로고
    • Double-hit B-cell lymphomas
    • Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319-2331.
    • (2011) Blood , vol.117 , Issue.8 , pp. 2319-2331
    • Aukema, S.M.1    Siebert, R.2    Schuuring, E.3
  • 77
    • 77954752069 scopus 로고    scopus 로고
    • Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab
    • Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360-3365.
    • (2010) J Clin Oncol , vol.28 , Issue.20 , pp. 3360-3365
    • Barrans, S.1    Crouch, S.2    Smith, A.3
  • 78
    • 70449589073 scopus 로고    scopus 로고
    • MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
    • Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-3537.
    • (2009) Blood , vol.114 , Issue.17 , pp. 3533-3537
    • Savage, K.J.1    Johnson, N.A.2    Ben-Neriah, S.3
  • 79
    • 79955868541 scopus 로고    scopus 로고
    • The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective
    • Salaverria I, Siebert R. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol. 2011;29(14):1835-1843.
    • (2011) J Clin Oncol , vol.29 , Issue.14 , pp. 1835-1843
    • Salaverria, I.1    Siebert, R.2
  • 80
    • 78751580704 scopus 로고    scopus 로고
    • Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL
    • Maruyama D, Watanabe T, Maeshima AM, et al. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol. 2010;92(5):732-743.
    • (2010) Int J Hematol , vol.92 , Issue.5 , pp. 732-743
    • Maruyama, D.1    Watanabe, T.2    Maeshima, A.M.3
  • 81
    • 84855281681 scopus 로고    scopus 로고
    • MYC + aggressive-B-cell lymphomas: Novel therapy of untreated Burkitt lymhoma (BL) and MYC + diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R
    • [Abstract 071]
    • Dunleavy K, Pittaluga S, Wayne AS, et al. MYC + aggressive-B-cell lymphomas: novel therapy of untreated Burkitt lymhoma (BL) and MYC + diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R. Ann Oncol. 2011;22(suppl 4). [Abstract 071].
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 4
    • Dunleavy, K.1    Pittaluga, S.2    Wayne, A.S.3
  • 82
    • 79953879650 scopus 로고    scopus 로고
    • Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma
    • Eberle FC, Rodriguez-Canales J, Wei L, et al. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica. 2011;96(4):558-566.
    • (2011) Haematologica , vol.96 , Issue.4 , pp. 558-566
    • Eberle, F.C.1    Rodriguez-Canales, J.2    Wei, L.3
  • 83
    • 84856646807 scopus 로고    scopus 로고
    • Untreated primary mediastinal B-cell (PMBL) and mediastinal Grey Zone (MGZL) lymphomas: Comparison of biological features and clinical outcome following DA-EPOCH-R without radiation
    • [Abstract 150]
    • Dunleavy K, Pittaluga S, Shovlin M, G et al. Untreated primary mediastinal B-cell (PMBL) and mediastinal Grey Zone (MGZL) lymphomas: comparison of biological features and clinical outcome following DA-EPOCH-R without radiation. Ann Oncol. 2011;22(suppl 4). [Abstract 150].
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 4
    • Dunleavy, K.1    Pittaluga, S.2    Shovlin, M.G.3
  • 84
    • 79952459294 scopus 로고    scopus 로고
    • Two cases of mediastinal gray zone lymphoma
    • Minami J, Dobashi N, Asai O, et al. Two cases of mediastinal gray zone lymphoma. J Clin Exp Hematop. 2010;50(2):143-149.
    • (2010) J Clin Exp Hematop , vol.50 , Issue.2 , pp. 143-149
    • Minami, J.1    Dobashi, N.2    Asai, O.3
  • 86
    • 0037142053 scopus 로고    scopus 로고
    • The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
    • Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947.
    • (2002) N Engl J Med , vol.346 , Issue.25 , pp. 1937-1947
    • Rosenwald, A.1    Wright, G.2    Chan, W.C.3
  • 87
    • 67650398258 scopus 로고    scopus 로고
    • Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
    • Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069-6076.
    • (2009) Blood , vol.113 , Issue.24 , pp. 6069-6076
    • Dunleavy, K.1    Pittaluga, S.2    Czuczman, M.S.3
  • 88
    • 79952154013 scopus 로고    scopus 로고
    • Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma
    • Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2010;29(6):690-697.
    • (2010) J Clin Oncol , vol.29 , Issue.6 , pp. 690-697
    • Ruan, J.1    Martin, P.2    Furman, R.R.3
  • 89
    • 70249128366 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: A rare clinicopathologic entity with poor prognosis
    • Laurent C, Do C, Gascoyne RD, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol. 2009;27(25):4211-4216.
    • (2009) J Clin Oncol , vol.27 , Issue.25 , pp. 4211-4216
    • Laurent, C.1    Do, C.2    Gascoyne, R.D.3
  • 91
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    • Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
    • (2010) N Engl J Med , vol.363 , Issue.18 , pp. 1693-1703
    • Kwak, E.L.1    Bang, Y.J.2    Camidge, D.R.3
  • 92
    • 80053190602 scopus 로고    scopus 로고
    • Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)
    • [abstract 8032]
    • Pro B. Durable remissions with brentuximab vedotin (SGN-35): updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) [abstract 8032]. J Clin Oncol. 2011;29(15S):512s.
    • (2011) J Clin Oncol , vol.29 , Issue.15 S
    • Pro, B.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.